# LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

> **NCT01726738** · PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Stage III Melanoma
- Stage IV Melanoma
- Unresectable Melanoma
- BRAF Mutant Melanoma

## Interventions

- **DRUG:** BRAF inhibitor dabrafenib and MEK inhibitor trametinib

## Key facts

- **NCT ID:** NCT01726738
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-04
- **Primary completion:** 2017-11-03
- **Final completion:** 2020-09-17
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01726738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01726738, "LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01726738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*